Screener
Enliven Therapeutics ELVN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Accounts payable | $1,640 | $2,159 |
| Accrued expenses and other current liabilities | 9,847 | 14,409 |
| Total current liabilities | 11,487 | 16,568 |
| Total liabilities | 11,487 | 16,568 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none | — | — |
| Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 60,889,655 and 59,440,045 atMarch 31, 2026 and December 31, 2025, respectively | 61 | 59 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's total liabilities?
- Enliven Therapeutics (ELVN) reported total liabilities of $11.49M in Q1 2026.
- How has Enliven Therapeutics's total liabilities changed year-over-year?
- Enliven Therapeutics's total liabilities decreased by 19.5% year-over-year, from $14.27M to $11.49M.
- What is the long-term trend for Enliven Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Enliven Therapeutics's total liabilities has grown at a 20.9% compound annual growth rate (CAGR), from $6.41M to $16.57M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Enliven Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude